ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study — Activities of Daily Living, Mild Cognitive Impairment)

Type: Informant-rated functional outcome measure Purpose: Assess ability to perform daily activities in mild cognitive impairment and early Alzheimer's disease Developer: Galasko et al., Alzheimer's Disease Cooperative Study (ADCS)[@galasko1997] Current use: Co-primary endpoint in LY-3372689 MAGNOLIA trial, and most early AD therapeutic trials

Overview

Type: Informant-rated functional outcome measure Purpose: Assess ability to perform daily activities in mild cognitive impairment and early Alzheimer's disease Developer: Galasko et al., Alzheimer's Disease Cooperative Study (ADCS)[@galasko1997] Current use: Co-primary endpoint in LY-3372689 MAGNOLIA trial, and most early AD therapeutic trials

Overview

The ADCS-MCI-ADL is a 24-item informant-rated scale developed by the Alzheimer's Disease Cooperative Study to assess functional abilities in patients with mild cognitive impairment["@galasko1997"]. Unlike performance-based cognitive tests, this scale relies on an informant (caregiver, family member) who observes the patient's daily functioning over time.

The scale was specifically designed for MCI populations where functional impairment is subtle but clinically meaningful. It captures the early loss of instrumental activities of daily living (IADLs) that distinguishes MCI from normal aging["@petersen2004"]. The ADCS-MCI-ADL has become the standard functional co-primary endpoint in early AD trials, typically paired with [ADAS-Cog](/entities/adas-cog) as the cognitive co-primary.

Structure

Item Categories

The 24 items are organized into three categories:

Basic Activities of Daily Living (6 items)

• Walking, bathing, grooming, dressing, eating, toilet hygiene
• Usually preserved in MCI; more relevant in moderate-severe AD

• Managing finances, medication management, shopping, meal preparation
• Household chores, use of appliances, travel, hobbies
• Communication (phone, mail), scheduling, orientation to time
• These items show the earliest decline in MCI

Scoring

• Each item scored 0 (dependent/no longer does) to 3 (normal)
• Maximum score: 60 (higher = better function)
• Range typically seen in MCI: 35–55
• Decline of 3–5 points over 18 months is typical in early AD placebo groups

Informant Requirements

• Must be someone who sees the patient regularly (weekly contact minimum)
• Knowledgeable about patient's daily activities
• Caregiver burden can affect reporting accuracy
• Must be consistent across study visits

Validation and Psychometrics

Reliability

• High test-retest reliability (r > 0.8)
• Strong inter-rater reliability
• Internal consistency (Cronbach's alpha > 0.85)

Sensitivity

• Detects early functional decline in MCI that MMSE misses
• Correlates with brain FDG-PET hypometabolism patterns[@zhu2006]
• Predictive of progression from MCI to AD dementia

Limitations

• Informant-dependent: bias from caregiver depression or burden
• Cultural/language adaptations needed
• May miss very subtle changes in pre-MCI stages
• Variable informant reliability across studies

Use in OGA Inhibitor Trials

MAGNOLIA Trial (LY-3372689 in Early AD)

• Population: Early symptomatic AD (amyloid-confirmed, MMSE 20–30)
• Co-primary endpoint: Change from baseline in ADCS-MCI-ADL at 18 months
• Expected change: Treatment group expected to show ~25–35% slowing of functional decline
• Rationale: OGA inhibition protecting tau pathology should preserve daily functioning

Why functional measures matter in tau trials

• Tau pathology correlates with functional decline as much as cognitive decline
• Patients and caregivers often notice functional changes before cognitive test deficits
• Regulatory agencies require both cognitive and functional endpoints for approval
• ADCS-MCI-ADL specifically designed for the MCI population being targeted

Comparison with Other Functional Scales

| Scale | Type | Max Score | Population | Notes |
|-------|------|-----------|-----------|-------|
| ADCS-MCI-ADL | Informant | 60 | MCI, early AD | 24 items, MCI-optimized |
| ADCS-ADL | Informant | 78 | Mild-severe AD | 23 items, broader AD range |
| FAQ | Informant | 30 | MCI, dementia | 10 items, more general |
| UPSIT | Performance | N/A | Research use | Smell identification |

Cross-Links

• [ADAS-Cog](/entities/adas-cog) — cognitive co-primary endpoint
• [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — target of OGA inhibitors
• [Yin-Yang Hypothesis](/mechanisms/yin-yang-hypothesis) — mechanism linking O-GlcNAc and phosphorylation
• [LY-3372689 MAGNOLIA Trial](/clinical-trials/ly3372689-magnolia-phase2-ad) — co-primary endpoint
• [PSP Rating Scale](/entities/psp-rating-scale) — analogous measure in PSP trials
• [Alzheimer's Disease](/diseases/alzheimers-disease) — primary disease context

See Also

• [BCL2 (B-Cell Lymphoma 2)](/wiki/proteins-bcl2) — targets